

In the Claims

Claims 1-27 (Cancelled).

Claim 28 (Previously Presented). A peptide of the sequence X-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-Y wherein X is selected from the group consisting of acetyl, n-butanoyl, n-hexanoyl, n-octanoyl, lauroyl, myristoyl, palmitoyl, isohexanoyl, cyclohexanoyl, cyclopentylcarbonyl, n-heptanoyl, n-decanoyl, n-undecanoyl and 3,7-dimethyloctanoyl and Y is a carboxy terminal residue selected from OH or amino; or a pharmaceutically acceptable salt thereof.

Claim 29 (Previously Presented). A peptide of the sequence Acetyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO:2) or a pharmaceutically acceptable salt thereof.

Claim 30 (Previously Presented). A peptide of the sequence n-Butanoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO:3) or a pharmaceutically acceptable salt thereof.

Claim 31 (Previously Presented). A peptide of the sequence n-Octanoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO:4) or a pharmaceutically acceptable salt thereof.

Claim 32 (Previously Presented). A peptide of the sequence Myristoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO:5) or a pharmaceutically acceptable salt thereof.

Claim 33 (Previously Presented). A peptide of the sequence Palmitoyl-Leu-Met-Tyr-Pro-Thr-Tyr-Leu-Lys-OH (SEQ ID NO:6) or a pharmaceutically acceptable salt thereof.

Claim 34 (Previously Presented). A composition comprising the peptide of claim 28 and a pharmaceutically acceptable carrier.

Claim 35 (Previously Presented). A composition comprising the peptide of claim 29 and a pharmaceutically acceptable carrier.

Claim 36 (Previously Presented). A composition comprising the peptide of claim

OK to enter
7/19/04 Amy